Company Description
OSR Health, Inc., a healthcare holding company, develops a portfolio of therapies and healthcare solutions in the United States, Europe, and Korea.
The company develops immunotherapy products, including VXM01, an immuno-oncology candidate for glioblastoma completed phase 2 clinical trial, as well as preclinical stage products, such as VXM04 to treat mesothelin; VXM06 for the treatment of Wilms Tumor Protein (WT1); VXM08 for Carcinoembryonic antigen (CEA); and VXM10 for PD-L1.
It is also developing design-augmented (DA) biologics comprising DRT-102, a clinical-stage asset for spinal fusion; and DRT-101, a pre-clinical stage asset for osteoarthritis.
In addition, the company distributes neurovascular intervention medical device and systems. The company was formerly known as OSR Holdings, Inc. and changed its name to OSR Health, Inc. in June 2026.
OSR Health, Inc. was incorporated in 2020 and is based in Bellevue, Washington.
| Country | United States |
| Founded | 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 22 |
| CEO | Kuk Hwang |
Contact Details
Address: 10900 NE 4th Street, Suite 2300 Bellevue, Washington 98004 United States | |
| Phone | 425 635 7700 |
| Website | osr-holdings.com |
Stock Details
| Ticker Symbol | OSRH |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001840425 |
| CUSIP Number | 68840D102 |
| ISIN Number | US68840D1028 |
| Employer ID | 84-5052822 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Kuk Hyoun Hwang | Chairman and Chief Executive Officer |
| Gihyoun Bang | Chief Financial Officer |
| Dr. Constance Hofer | Chief Scientific Officer |
| Jun Chul Whang | Chief Legal Officer, Secretary and Director |
| Tim Smith | Corporate Secretary and Global IR |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 17, 2026 | 8-K | Current Report |
| Jun 11, 2026 | 8-K | Current Report |
| Jun 11, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Jun 2, 2026 | 8-K | Current Report |
| May 26, 2026 | DEF 14A | Other definitive proxy statements |
| May 13, 2026 | 10-Q | Quarterly Report |
| May 11, 2026 | PRE 14A | Other preliminary proxy statements |
| May 6, 2026 | 8-K/A | [Amend] Current report |
| Apr 30, 2026 | 8-K | Current Report |
| Apr 22, 2026 | SCHEDULE 13G | Filing |